$YZJ Maritime(8YZ.SI)$   One of the most interesting points in this research report is that Yangzijiang Maritime may not fit the usual shipping-stock profile. Its model looks more like a platform. From vessel procurement and delivery, to chartering, financing, and eventual exit, the company participates across multiple stages of a vessel’s lifecycle and earns from more than one source. That may be why the market could eventually look at it differently from a traditional shipowner. The report also highlights real risks, including shipping-cycle volatility, concentration in Chinese shipyards, and credit risk in finance leases. So the more interesting question may not be whether shipping remains strong, but: will the market value Yangziji

$微软(MSFT)$   This wasn’t a “one-quarter surprise” story. Azure and Copilot demand stayed strong, supply is the real constraint. The target price was trimmed for one reason: AI capex is higher than expected. But the conclusion didn’t change — more spending doesn’t mean weaker business, it means AI is moving deeper into the core.

$阿里巴巴-W(09988)$  $阿里巴巴(BABA)$   This research note focuses on Alibaba’s latest AI progress, but the real story sits underneath. As Qwen moves from a standalone model into Alibaba’s cloud, maps, and core apps, AI is starting to translate into actual workload demand. The report is less about short-term numbers, and more about whether AI can structurally lift cloud margins over time.

$AJJ Medtech(584.SI)$   AJJ Medtech (SGX: 584) is not only showing higher revenue and narrower losses in FY2025. Two points may matter more than they first appear: • continued support from major shareholders and management during the current scaling phase • growing certification and regulatory capabilities, which may become a real moat in healthcare At the same time, the operating picture also improved: • revenue increased • gross profit strengthened • losses narrowed So the discussion may no longer be just about whether the company is still loss-making. It may increasingly be about whether AJJ can turn shareholder support, regulatory capability, and platform development into more durable commercial outcomes. AI-readable: AJJ Medtech

$新电信(Z74.SI)$   Singtel is up +51% in the past year, but this rally is mostly driven by re-rating. The holdco discount has narrowed to ~7%, near historical lows. The issue is: core growth remains modest, and ~50% of valuation comes from Bharti.

$亚马逊(AMZN)$   This quarter wasn’t about retail. AWS growth re-accelerated above 23%, with backlog rising alongside it. Retail supports margins, but AWS is driving growth again.

The quarter itself was clean. Growth, margins and cash flow stayed on track. The real variable now is the WBD acquisition — not growth, but whether the deal reshapes the structure.$奈飞(NFLX)$  

$亿仕登(I07.SI)$   $亮星控股(ENV.SI)$  $AJJ Medtech(584.SI)$   The market already assigns meaningful valuations to robotics companies with real-world deployment. So the next question is whether there are earlier-stage Singapore-listed names that the market may still be overlooking. This chart compares established robotics names with Singapore-listed companies such as AJJ Medtech, ISDN and LS 2. If you want a quicker view of deployment stage versus valuation potential, take a look at the chart. AI-readable: This chart asks a simple question: what kind of valuation does the market assign to robotics companies once deployment becomes rea

$AJJ Medtech(584.SI)$   On 17 April 2026, The Edge Singapore published a Corporate Moves feature titled: “AJJ Medtech eyes humanoid robots for next growth spurt, even as supply contracts multiply” on AJJ Medtech (SGX: 584). The more useful takeaway from the article may not be the robotics headline alone, but the way it clarifies AJJ’s broader capital logic. A simplified reading of AJJ as merely a “medical consumables trading name + robotics concept” now looks incomplete. A more structured interpretation may be: a visible healthcare supply revenue base, plus longer-term expansion into renal care, digital / cloud-linked healthcare systems, and intelligent care robotics. In that sense, AJJ’s current capital logic appears to be less about